Identification of somatic mutations in parathyroid tumors using whole-exome sequencing.

CONTEXT The underlying molecular alterations causing sporadic parathyroid adenomas that drive primary hyperparathyroidism have not been thoroughly defined. OBJECTIVE The aim of the study was to investigate the occurrence of somatic mutations driving tumor formation and progression in sporadic parathyroid adenoma using whole-exome sequencing. DESIGN Eight matched tumor-constitutional DNA pairs from patients with sporadic parathyroid adenomas underwent whole-exome capture and high-throughput sequencing. Selected genes were analyzed for mutations in an additional 185 parathyroid adenomas. RESULTS Four of eight tumors displayed a frame shift deletion or nonsense mutation in MEN1, which was accompanied by loss of heterozygosity of the remaining wild-type allele. No other mutated genes were shared among the eight tumors. One tumor harbored a Y641N mutation of the histone methyltransferase EZH2 gene, previously linked to myeloid and lymphoid malignancy formation. Targeted sequencing in the additional 185 parathyroid adenomas revealed a high rate of MEN1 mutations (35%). Furthermore, this targeted sequencing identified an additional parathyroid adenoma that contained the identical, somatic EZH2 mutation that was found by exome sequencing. CONCLUSION This study confirms the frequent role of the loss of heterozygosity of chromosome 11 and MEN1 gene alterations in sporadic parathyroid adenomas and implicates a previously unassociated methyltransferase gene, EZH2, in endocrine tumorigenesis.

[1]  Annabelle L. Fonseca,et al.  Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas , 2012, Endocrine.

[2]  R. Lifton,et al.  The DNA methylome of benign and malignant parathyroid tumors , 2011, Genes, chromosomes & cancer.

[3]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[4]  S. Mane,et al.  K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.

[5]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[6]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[7]  J. Licht,et al.  Deregulation of H3K27 methylation in cancer , 2010, Nature Genetics.

[8]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[9]  B. Harding,et al.  Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia , 2009, Endocrine-related cancer.

[10]  I. Tikhonova,et al.  Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.

[11]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[12]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[13]  Bin Tean Teh,et al.  Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.

[14]  X. Hua,et al.  Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. , 2008, Current molecular medicine.

[15]  R. Durbin,et al.  Mapping Quality Scores Mapping Short Dna Sequencing Reads and Calling Variants Using P

, 2022 .

[16]  C. Stratakis,et al.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene , 2008, Human mutation.

[18]  G. Åkerström,et al.  An LRP5 Receptor with Internal Deletion in Hyperparathyroid Tumors with Implications for Deregulated WNT/β-Catenin Signaling , 2007, PLoS medicine.

[19]  T. Tuttle,et al.  Trends in the incidence and treatment of parathyroid cancer in the United States , 2007, Cancer.

[20]  C. Preudhomme,et al.  Mutation in RAP1 is a rare event in myelodysplastic syndromes , 2005, Leukemia.

[21]  O. Rozenblatt-Rosen,et al.  Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Chayvialle,et al.  Reduction of Menin Expression Enhances Cell Proliferation and Is Tumorigenic in Intestinal Epithelial Cells* , 2004, Journal of Biological Chemistry.

[23]  W. Zong,et al.  Menin Induces Apoptosis in Murine Embryonic Fibroblasts* , 2004, Journal of Biological Chemistry.

[24]  G. Kay,et al.  Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. , 2004, Molecular cell.

[25]  T. Carling,et al.  Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. , 2003, Surgery.

[26]  J. Carpten,et al.  Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. , 2003, The New England journal of medicine.

[27]  Jun O. Liu,et al.  Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. , 2003, Cancer research.

[28]  D. Hanahan,et al.  Of Mice and MEN1: Insulinomas in a Conditional Mouse Knockout , 2003, Molecular and Cellular Biology.

[29]  A. D’Andrea,et al.  Menin associates with FANCD2, a protein involved in repair of DNA damage. , 2003, Cancer research.

[30]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[31]  A. Arnold,et al.  Molecular pathogenesis of primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  F. Collins,et al.  The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation , 2001, Oncogene.

[33]  G. Hendy,et al.  Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Carling.  Molecular pathology of parathyroid tumors , 2001, Trends in Endocrinology & Metabolism.

[35]  F. Collins,et al.  Characterization of a MEN1 ortholog from Drosophila melanogaster. , 2001, Gene.

[36]  F. Collins,et al.  Menin Interacts with the AP1 Transcription Factor JunD and Represses JunD-Activated Transcription , 1999, Cell.

[37]  C. Larsson,et al.  Characterization of the mouse Men1 gene and its expression during development , 1998, Oncogene.

[38]  J. Rastad,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Parathyroid MEN1 Gene Mutations in Relation to Clinical Characteristics of Nonfamilial Primary Hyperparathyroidism* , 2022 .

[39]  N. Palanisamy,et al.  Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[40]  F. Collins,et al.  Menin, the product of the MEN1 gene, is a nuclear protein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Forbes,et al.  Characterization of mutations in patients with multiple endocrine neoplasia type 1. , 1998, American journal of human genetics.

[42]  F. Collins,et al.  Somatic mutation of the MEN1 gene in parathyroid tumours , 1997, Nature Genetics.

[43]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[44]  E. Thurfjell,et al.  Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.

[45]  J. Marks,et al.  p53 in Human Cancer , 1995 .

[46]  D. Louis,et al.  p53 abnormalities in human parathyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[47]  A. Thor,et al.  Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. , 1994, The New England journal of medicine.

[48]  R. Eddy,et al.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. , 1989, The Journal of clinical investigation.

[49]  Edis Aj,et al.  Parathyroid "double adenomas": fact of fiction? , 1981 .

[50]  Saudi Arabia,et al.  in the United States and in , 1981 .

[51]  A. Edis,et al.  Parathyroid "double adenomas": fact of fiction? , 1981, Surgery.